Table 2.
Extracted data from patients reporting malignant transformation following denosumab.
| Ref. | NoP | Transformation n (%) |
Time to Malignant Transformation From GCTB | FU |
|---|---|---|---|---|
| Rutkowski et al. [3] | 222 | 2 (0.9%) | 8.6 mo | Median 13.0 mo |
| Chawla et al. [7,8] | 526 | 5 (<1%) | Range, 17 mo–11 yr | Median 58.1 mo |
| Agarwal et al. [9] | 25 | 1 (4%) | 8 mo | 27 mo |
| Treffel et al. [10] | 35 | 1 (2.9%) | 18 mo | NR |
| Perrin et al. [11] | 25 | 1 (4%) | 55 mo | Median 57 mo |
| Palmerini et al. [12] |
526 | 14 (2.6%) | 7.8 yr | 58 mo |
All patients received 120 mg of denosumab q28, plus loading dose with 120 mg on D8 and D15 FU: follow-up; GCTB: giant cell tumour of bone; mo: months; n: number; NoP: numbers of patients; NR: not reported; Ref: references; yr: years.